All In MedTech

Device Trial Radar · NCT00100087

Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System

A Safety and Feasibility Study of the TheraSight(TM) Ocular Brachytherapy System for Treatment of Age-Related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Actual

Start

Oct 2004

Primary completion

Not stated

Sponsor

Lead sponsor
Theragenics CorporationNot on our public-company list
Sponsor type
Industry
First posted
Dec 23, 2004

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).

Conditions

  • Macular Degeneration
  • Choroidal Neovascularization

Interventions

  • Ocular BrachytherapyDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of serious adverse events 30 to 270 days after treatment

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Theragenics Clinical Site

    Atlanta, Georgia · Recruiting

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.